Analyst Predicts High Probability of Positive Data for Nyxoah Sa's DREAM Study

By Don Francis, Editor
February 10, 2024 11:31 AM UTC
Analyst Predicts High Probability of Positive Data for Nyxoah Sa's DREAM Study

Cantor Fitzgerald's Ross Osborn raised their price target on Nyxoah Sa (NASDAQ: NYXH) by 40% from $10 to $14 on 2024/02/09. The analyst maintained their Strong Buy rating on the stock.

Osborn's optimistic outlook stems from the upcoming DREAM U.S. pivotal study and the release of efficacy and safety data by early April 2024. According to the analyst, the probability of positive data from the study and subsequent FDA approval are both high.

One of the key factors contributing to Osborn's bullish sentiment is Nyxoah's innovative product, Genio. The analyst highlighted its unique design, which includes a single incision, an external battery, and improved MRI compatibility. Osborn believes that these features position Genio for widespread adoption in the U.S. market.

The market seems to agree with Cantor Fitzgerald's assessment, as 100% of top-rated analysts currently rate NYXH as a Strong Buy or Buy. Not a single analyst sees the stock as a Hold, and there are no recommendations to sell.

Investors who have been holding NYXH shares have likely seen substantial gains. Year-over-year, the stock has surged by an impressive 142.5%. This growth significantly outpaces the broader market, with the S&P 500 only up 23.2% during the same period.

Ross Osborn, the analyst behind this latest price target raise, has established a solid reputation in the financial industry. WallStreetZen ranks Osborn in the top 22% out of 4,470 Wall Street analysts, with an average return of 7% and a notable win rate of 52.3%. The analyst specializes in the Healthcare sector, bringing expertise and insights to their analysis.

Nyxoah S.A., the company behind Genio, is a health-tech firm focused on developing solutions for sleep-disordered breathing conditions, including severe Obstructive Sleep Apnea. This common condition is associated with increased mortality risk and comorbidities such as cardiovascular diseases, depression, and stroke. Nyxoah, founded in 2009, is headquartered in Mont-Saint-Guibert, Belgium.

Get free updates on Nyxoah Sa

WallStreetZen tracks the performance of nearly 4,000 Wall Street analysts, whom we rank by average returns, frequency, and win-rate (backtested over multiple years).

Create a free watchlist and be the first to know when top-rated Wall Street analysts revise their Nyxoah Sa stock forecast.

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen and Don Francis do not hold any positions in the companies mentioned in this article. The information and statistics provided herein are presented for general informational purposes only and may not be accurate, complete, or up-to-date. It should not be interpreted as a recommendation to buy or sell any stocks and should not be solely relied upon for making investment decisions. It does not take into account your financial situation or risk profile. All investors should conduct their own investment due diligence before buying a stock. WallStreetZen expressly disclaims any liability for the accuracy, reliability, or completeness of the analysts' information, price targets, ratings, or opinions.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.